Clinical Research Directory
Browse clinical research sites, groups, and studies.
Safety and Efficacy of ADVM-022 in Treatment-Experienced Patients With Neovascular Age-related Macular Degeneration [LUNA]
Sponsor: Adverum Biotechnologies, Inc.
Summary
Neovascular or wet age-related macular degeneration (nAMD) is a degenerative ocular disease associated with the infiltration of abnormal blood vessels in the retina from the underlying choroid layer and is a leading cause of blindness in patients over 65 years of age. The abnormal angiogenic process in nAMD is stimulated and modulated by vascular endothelial growth factor (VEGF). Treatment of nAMD requires frequent intravitreal (IVT) injections of VEGF inhibitors (anti-VEGF) administered every 4-16 weeks. ADVM-022 (AAV.7m8-aflibercept) is a gene therapy product being developed for the treatment of nAMD and offers the potential for sustained intraocular expression of aflibercept following a single IVT injection. ADVM-022 is designed to reduce the current treatment burden which often results in undertreatment and vision loss in patients with nAMD receiving anti-VEGF therapy in clinical practice.
Official title: A Multi-Center, Randomized, Double-Masked Phase 2 Study to Assess Safety and Efficacy of ADVM-022 (AAV.7m8-aflibercept) in Anti-VEGF Treatment-Experienced Patients With Neovascular (Wet) Age-related Macular Degeneration (nAMD) [LUNA]
Key Details
Gender
All
Age Range
50 Years - Any
Study Type
INTERVENTIONAL
Enrollment
69
Start Date
2022-08-23
Completion Date
2028-08
Last Updated
2025-08-22
Healthy Volunteers
No
Interventions
ADVM-022
A single IVT injection of 2E11 vg/eye ADVM-022 dose in combination with one (1) of four (4) corticosteroid treatment regimens
ADVM-022
A single IVT injection of 6E10 vg/eye ADVM-022 dose in combination with one (1) of four (4) corticosteroid treatment regimens
Locations (39)
Adverum Clinical Site 178
Phoenix, Arizona, United States
Adverum Clinical Site 126
Phoenix, Arizona, United States
Adverum Clinical Site 159
Tucson, Arizona, United States
Adverum Clinical Site 100
Beverly Hills, California, United States
Adverum Clinical Site 172
Encino, California, United States
Adverum Clinical Site 169
Fullerton, California, United States
Adverum Clinical Site 170
Pasadena, California, United States
Adverum Clinical Site 174
Poway, California, United States
Adverum Clinical Site 164
Riverside, California, United States
Adverum Clinical Site 166
Sacramento, California, United States
Adverum Clinical Site 175
Santa Barbara, California, United States
Adverum Clinical Site 116
Lakewood, Colorado, United States
Adverum Clinical Site 165
Waterford, Connecticut, United States
Adverum Clinical Site 124
Deerfield Beach, Florida, United States
Adverum Clinical Site 176
Fort Lauderdale, Florida, United States
Adverum Clinical Site 168
Jacksonville, Florida, United States
Adverum Clinical Site 149
‘Aiea, Hawaii, United States
Adverum Clinical Site 167
Detroit, Michigan, United States
Adverum Clinical Site 161
Royal Oak, Michigan, United States
Adverum Clinical Site 163
Southaven, Mississippi, United States
Adverum Clinical Site 177
Omaha, Nebraska, United States
Adverum Clinical Site 119
Reno, Nevada, United States
Adverum Clinical Site 146
Cherry Hill, New Jersey, United States
Adverum Clinical Site 171
Teaneck, New Jersey, United States
Adverum Clinical Site 122
West Columbia, South Carolina, United States
Adverum Clinical Site 144
Rapid City, South Dakota, United States
Adverum Clinical Site 101
Nashville, Tennessee, United States
Adverum Clinical Site 123
Abilene, Texas, United States
Adverum Clinical Site 154
Austin, Texas, United States
Adverum Clinical Site 108
Bellaire, Texas, United States
Adverum Clinical Site 162
McAllen, Texas, United States
Adverum Clinical Site 151
San Antonio, Texas, United States
Adverum Clinical Site 107
The Woodlands, Texas, United States
Adverum Clinical Site 152
Morgantown, West Virginia, United States
Adverum Clinical Site 502
Nantes, Loire-Atlantique, France
Adverum Clinical Site 501
Lyon, Rhône, France
Adverum Clinical Site 500
Créteil, Val-de-Marne, France
Adverum Clinical Site 600
London, United Kingdom
Adverum Clinical Site 601
Oxford, United Kingdom